A Lancet study finds that natural immunity against severe COVID-19 is strong and long-lasting for all variants in previously infected individuals. However, protection against Omicron BA.1 reinfection is reduced for those with past pre-Omicron infections. Researchers stress that vaccination is still the safest way to acquire immunity.
- Largest review and meta-analysis assessing the extent of protection following COVID-19 infection by variant and how durable that protection is against different variants, including 65 studies from 19 countries.
- For people who have been infected with COVID-19 at least once before, natural immunity against severe disease (hospitalization and death) was strong and long-lasting for all variants (88% or greater at 10 months post-infection).
- Past infection with pre-Omicron variants provided substantially reduced natural immunity protection against reinfection with Omicron BA.1 (36% at 10 months after infection).
- The researchers say we should recognize the natural immunity in people who have recently been infected with COVID-19, but warn that their findings should not discourage vaccination because it is the safest way to acquire immunity.
For someone previously infected with COVID-19, their risk of hospitalization or death is 88% lower for at least 10 months compared to those who had not been previously infected, according to a systematic review and meta-analysis published in The Lancet.
The analysis also suggests that the level and duration of protection against reinfection, symptomatic disease, and severe illness is at least on a par with that provided by two doses of the mRNA vaccines (Moderna, Pfizer-BioNtech) for ancestral, Alpha, Delta, and Omicron BA.1 variants. The study did not include data on infection from Omicron XBB and its sublineages.
As IHME co-author Dr. Caroline Stein explains: "Vaccines continue to be important for everyone in order to protect high-risk populations such as those who are over 60 years of age and those with comorbidities. This also includes populations that have not previously been infected and unvaccinated groups, as well as those who were infected or received their last vaccine dose more than six months ago. Decision makers should take both natural immunity and vaccination status into consideration to obtain a full picture of an individual's immunity profile."
Since January 2021, several studies and reviews have reported the effectiveness of past COVID-19 infection in reducing the risk of reinfection and how immunity wanes over time. But none has comprehensively assessed how long the protection after natural infection will last and how durable that protection will be against different variants.
To provide more evidence, the researchers conducted a review and meta-analysis of all previous studies that compared the reduction in risk of COVID-19 among non-vaccinated individuals against a SARS-CoV-2 reinfection to non-vaccinated individuals without a previous infection up to September 2022.
It included 65 studies from 19 countries (Austria, Belgium, Brazil, Canada, Czechia, Denmark, France, India, Italy, Netherlands, Nicaragua, Norway, Qatar, Scotland, South Africa, Sweden, Switzerland, the UK, and the USA) and evaluates the effectiveness of past infection by outcome (infection, symptomatic disease, and severe disease), variant, and time since infection. Studies examining natural immunity in combination with vaccination (i.e., hybrid immunity) were excluded from the analyses.
Immunity fades over time
Analysis of data from 21 studies reporting on time since infection from a pre-Omicron variant estimated that protection against reinfection from a pre-Omicron variant was about 85% at one month—and this fell to about 79% at 10 months. Protection from a pre-Omicron variant infection against reinfection from the Omicron BA.1 variant was lower (74% at one month) and declined more rapidly to 36% at around 10 months.
Nevertheless, analysis of five studies reporting on severe disease (hospitalization and death) found that protection remained universally high for 10 months: 90% for ancestral, Alpha, and Delta, and 88% for Omicron BA.1.
Six studies evaluating protection against Omicron sub-lineages specifically (BA.2 and BA.4/BA.5) suggested significantly reduced protection when the prior infection was pre-Omicron variant. But when the past infection was Omicron, protection was maintained at a higher level.
"The weaker cross-variant immunity with the Omicron variant and its sub-lineages reflects the mutations they have that make them escape built-up immunity more easily than other variants," says IHME co-author Dr. Hasan Nassereldine. "The limited data we have on natural immunity protection from the Omicron variant and its sub-lineages underscores the importance of continued assessment, particularly since they are estimated to have infected 46% of the global population between November 2021 and June 2022. Further research is also needed to assess the natural immunity of emerging variants and to examine the protection provided by combinations of vaccination and natural infection."
The researchers note some limitations of their study, cautioning that the number of studies examining the Omicron BA.1 variant and its sub-lineages and the number from Africa was generally limited. In addition, only limited data were available beyond 10 months after the initial infection. They also note that some information, such as past infection status and hospital admissions, was measured differently or incomplete, and could bias the estimate of protection.
Writing in a linked Comment, Professor Cheryl Cohen, National Institute for Communicable Diseases, South Africa, who was not involved in the study, says, "The high and sustained levels of protection conferred by previous infection against severe disease have important implications for COVID-19 vaccine policy. By September 2021, global SARS CoV-2 seroprevalence was estimated at 59%, with substantial variation in the proportion of immunity induced by infection or vaccination in different settings. Seroprevalence in Africa was estimated at 87% in December 2021, largely as a result of infection. High levels of immunity are an important contributor to the lower levels of severity observed with infection caused by emerging Omicron subvariants. As SARS-CoV-2 epidemiology shifts to more stable circulation patterns in the context of high levels of immunity, studies of the burden and cost of SARS-CoV-2 infection and risk groups for severe disease are needed to guide rational vaccination policy and decisions around prioritization in relation to other vaccine-preventable diseases."
News
Platelet-inspired nanoparticles could improve treatment of inflammatory diseases
Scientists have developed platelet-inspired nanoparticles that deliver anti-inflammatory drugs directly to brain-computer interface implants, doubling their effectiveness. Scientists have found a way to improve the performance of brain-computer interface (BCI) electrodes by delivering anti-inflammatory drugs directly [...]
After 150 years, a new chapter in cancer therapy is finally beginning
For decades, researchers have been looking for ways to destroy cancer cells in a targeted manner without further weakening the body. But for many patients whose immune system is severely impaired by chemotherapy or radiation, [...]
Older chemical libraries show promise for fighting resistant strains of COVID-19 virus
SARS‑CoV‑2, the virus that causes COVID-19, continues to mutate, with some newer strains becoming less responsive to current antiviral treatments like Paxlovid. Now, University of California San Diego scientists and an international team of [...]
Lower doses of immunotherapy for skin cancer give better results, study suggests
According to a new study, lower doses of approved immunotherapy for malignant melanoma can give better results against tumors, while reducing side effects. This is reported by researchers at Karolinska Institutet in the Journal of the National [...]
Researchers highlight five pathways through which microplastics can harm the brain
Microplastics could be fueling neurodegenerative diseases like Alzheimer's and Parkinson's, with a new study highlighting five ways microplastics can trigger inflammation and damage in the brain. More than 57 million people live with dementia, [...]
Tiny Metal Nanodots Obliterate Cancer Cells While Largely Sparing Healthy Tissue
Scientists have developed tiny metal-oxide particles that push cancer cells past their stress limits while sparing healthy tissue. An international team led by RMIT University has developed tiny particles called nanodots, crafted from a metallic compound, [...]
Gold Nanoclusters Could Supercharge Quantum Computers
Researchers found that gold “super atoms” can behave like the atoms in top-tier quantum systems—only far easier to scale. These tiny clusters can be customized at the molecular level, offering a powerful, tunable foundation [...]
A single shot of HPV vaccine may be enough to fight cervical cancer, study finds
WASHINGTON -- A single HPV vaccination appears just as effective as two doses at preventing the viral infection that causes cervical cancer, researchers reported Wednesday. HPV, or human papillomavirus, is very common and spread [...]
New technique overcomes technological barrier in 3D brain imaging
Scientists at the Swiss Light Source SLS have succeeded in mapping a piece of brain tissue in 3D at unprecedented resolution using X-rays, non-destructively. The breakthrough overcomes a long-standing technological barrier that had limited [...]
Scientists Uncover Hidden Blood Pattern in Long COVID
Researchers found persistent microclot and NET structures in Long COVID blood that may explain long-lasting symptoms. Researchers examining Long COVID have identified a structural connection between circulating microclots and neutrophil extracellular traps (NETs). The [...]
This Cellular Trick Helps Cancer Spread, but Could Also Stop It
Groups of normal cbiells can sense far into their surroundings, helping explain cancer cell migration. Understanding this ability could lead to new ways to limit tumor spread. The tale of the princess and the [...]
New mRNA therapy targets drug-resistant pneumonia
Bacteria that multiply on surfaces are a major headache in health care when they gain a foothold on, for example, implants or in catheters. Researchers at Chalmers University of Technology in Sweden have found [...]
Current Heart Health Guidelines Are Failing To Catch a Deadly Genetic Killer
New research reveals that standard screening misses most people with a common inherited cholesterol disorder. A Mayo Clinic study reports that current genetic screening guidelines overlook most people who have familial hypercholesterolemia, an inherited disorder that [...]
Scientists Identify the Evolutionary “Purpose” of Consciousness
Summary: Researchers at Ruhr University Bochum explore why consciousness evolved and why different species developed it in distinct ways. By comparing humans with birds, they show that complex awareness may arise through different neural architectures yet [...]
Novel mRNA therapy curbs antibiotic-resistant infections in preclinical lung models
Researchers at the Icahn School of Medicine at Mount Sinai and collaborators have reported early success with a novel mRNA-based therapy designed to combat antibiotic-resistant bacteria. The findings, published in Nature Biotechnology, show that in [...]
New skin-permeable polymer delivers insulin without needles
A breakthrough zwitterionic polymer slips through the skin’s toughest barriers, carrying insulin deep into tissue and normalizing blood sugar, offering patients a painless alternative to daily injections. A recent study published in the journal Nature examines [...]
